EGFR and neoplasm: EGFR amplification has also been identified as a main molecular alteration at the first-line treatment failure of osimertinib, occurring in 3.7% (1/27),22 19.0% (4/21),21 and 23.9% (11/46)23 of patients by tumor tissue detection.